Thrivent Financial for Lutherans
FATE icon

Thrivent Financial for Lutherans’s Fate Therapeutics FATE Stock Holding History

Thrivent Financial for Lutherans’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$41K Hold
34,105
– – ﹤0.01% 2518
2025
Q4 		$34K Hold
34,105
– – ﹤0.01% 2557
2025
Q3 		$43K Sell
34,105
-3,011
-8% -$3.25K ﹤0.01% 2359
2025
Q2 		$41K Sell
37,116
-52,206
-58% -$60.7K ﹤0.01% 2421
2025
Q1 		$71K Hold
89,322
– – ﹤0.01% 2350
2024
Q4 		$148K Sell
89,322
-36,048
-29% -$90.8K ﹤0.01% 2528
2024
Q3 		$439K Buy
125,370
+24,804
+25% +$96.5K ﹤0.01% 2295
2024
Q2 		$330K Buy
+100,566
New +$440K ﹤0.01% 2359

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Thrivent Financial for Lutherans's FATE Position: Q1 2026 in Review

Thrivent Financial for Lutherans held its Fate Therapeutics (FATE) position steady in Q1 2026 at 34,105 shares worth $41K. The position accounts for ﹤0.01% of the portfolio, ranked #2518.

Thrivent Financial for Lutherans first reported a position in FATE in Q2 2024 and has held it in 8 quarters since. The position peaked at $439K in Q3 2024. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • Thrivent Financial for Lutherans held 34,105 shares of Fate Therapeutics worth $41K as of Q1 2026.
  • Thrivent Financial for Lutherans left its Fate Therapeutics share count unchanged in Q1 2026.
  • Fate Therapeutics made up ﹤0.01% of Thrivent Financial for Lutherans's portfolio in Q1 2026, its #2518 holding.
  • Thrivent Financial for Lutherans first reported a position in Fate Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Thrivent Financial for Lutherans's Fate Therapeutics position peaked at $439K in Q3 2024.
  • 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on Thrivent Financial for Lutherans's 13F filing for Q1 2026, filed 1 May 2026.